Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2016

View Archived Issues

Bio-Path completes the safety portion of phase II trial evaluating BP-1001 in AML

TGV Laboratories outlines discovery of MV-4 with antiviral potential

Collaboration to evaluate avelumab in combination with defactinib in ovarian cancer

Syndax prices its initial public offering

Bristol-Myers Squibb patents ROCK2 inhibitors

Tesevatinib receives FDA orphan drug designation for the treatment of ARKPD

Cornell University describes immunoproteasome inhibitors

ContraVir demonstrates safety of FV-100 in drug-drug interaction study

Versitech and State Key Laboratory of Natural Product Chemistry report agents for liver disease

Novel vaccines and blood safety measures to combat global Zika virus outbreak

Rainbow Medical and Medos collaborate to treat spinal degenerative disc disease

PRAME oncogene expression is a prognostic biomarker in uveal melanoma

Hydra Biosciences presents TRPC5 antagonists

Onconova receives notice of termination from Baxalta regarding rigosertib agreement

MediSynergics divulges antiprotozoal compounds

Merck KGaA collaborates with EMBL to study cancer metabolism

Cyclic form of AChE-derived peptide as novel therapeutic approach in Alzheimer's disease

Yuhan Corporation and Sorrento Therapeutics form joint venture company

Ensemble achieves early-stage research milestone in Alexion collaboration

FDA grants orphan drug designation to BHV-0223 for spinocerebellar ataxia

Grunenthal and Axxam collaborate in pain and inflammation

Small molecule GS-5734 protects monkeys from Ebola virus disease

CaM-dependent RyR2 inhibitor shows promise for the treatment of arrhythmias

Phase II trial investigates intraductal administration of fulvestrant in DCIS or breast cancer

Encochleated amikacin receives FDA orphan drug designation for NTM infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...